New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What has been Investigated and What is in the Pipeline?

A wide range of support is available to help smokers to quit and aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. Despite the efficacy of these, there is a continual need to diversify the range of medications so that the needs of tobacco users are met. This paper compares the first-line smoking cessation medications to: 1) two variants of these existing products: new galenic formulations of varenicline and novel nicotine delivery devices; and 2) twenty-four alternative products: cytisine (novel outside of central and eastern Europe), nortriptyline, other tricyclic antidepressants, electronic cigarettes, clonidine (an anxiolytic), other anxiolytics (e.g. buspirone), selective 5-hydroxytryptamine (5-HT) reuptake inhibitors, supplements (e.g. St John’s wort), silver acetate, nicobrevin, modafinil, venlafaxine, monoamine oxidase inhibitors (MAOI), opioid antagonist, nicotinic acetylcholine receptors (nAChR) antagonists, glucose tablets, selective cannabinoid type 1 receptor antagonists, nicotine vaccines, drugs that affect gamma-aminobutyric acid (GABA) transmission, drugs that affect N-methyl-D-aspartate receptors (NMDA), dopamine agonists (e.g. levodopa), pioglitazone (Actos; OMS405), noradrenaline reuptake inhibitors, and the weight management drug lorcaserin. Six criteria are used: relative efficacy, relative safety, relative cost, relative use (overall impact of effective medication use), relative scope (ability to serve new groups of patients), and relative ease of use (ESCUSE). Many of these products are in the early stages of clinical trials, however, cytisine looks most promising in having established efficacy and safety and being of low cost. Electronic cigarettes have become very popular, appear to be efficacious and are safer than smoking, but issues of continued dependence and possible harms need to be considered

Chiral Separations Using a Modified Water Stationary Phase in Supercritical Fluid Chromatography

A novel means of achieving chiral separations in supercritical fluid chromatography (SFC) using a water stationary phase is presented. By adding various chiral selectors to the phase, different chiral analytes can be readily separated using neat CO2 as a mobile phase. For example, by adding β-cyclodextrin, it is found that certain flavanone enantiomers can be separated, while using the antibiotic vancomycin as a selector provides separation of some chiral phenoxypropionic acids. Other additives such as sodium chloride and triethylamine are also explored and found to enhance certain separations when also present in the water phase. While column pressure has a moderate impact on chiral analyte retention and separation in this SFC method, column temperature has a comparatively larger influence. In particular, relatively cooler temperatures below about 5 °C are found to markedly increase resolution and selectivity. For instance, notably large resolution of 4.7 is achieved for a phenoxypropionic acid pair at 0 °C and 150 atm CO2. Since the method does not require modifier to elute such polar species, it is also readily compatible with FID detection and does not generate organic waste. Therefore, results indicate that this approach could be a potentially simple and flexible means of achieving chiral separations in SFC.Natural Sciences and Engineering Research Council - Discovery Gran

Shade induced changes in biomechanical petiole properties in the stoloniferous herb Trifolium repens

Contains fulltext : 72614.pdf (publisher's version ) (Closed access